Coronary drug-eluting stent wars: Paclitaxel versus Everolimus

Results from the SPIRIT IV trial, comparing safety and efficacy of everolimus-eluting and Paclitaxel-eluting stents in treatment of coronary lesions, were described today (see link), below: 

SAN FRANCISCO, CA SEPTEMBER 23, 2009 Late-breaking data from SPIRIT IV, a large-scale multi-center study of nearly 4,000 patients in the U.S., shows that an everolimus-eluting stent demonstrated enhanced safety and efficacy in the treatment of de novo native coronary artery lesions when compared to a paclitaxel-eluting stent, and showed that "low late loss" may be achieved with drug-eluting stents without sacrificing safety.
 
As intense as the original competition was between Boston Scientific (TAXUS, Paclitaxel) and J&J/Cordis (CYPHER, Sirolimus), the competition in the stent wars is heating up with the apparent efficacy of Everolimus (Abbott and others, including Boston Scientific) and a litany of other drugs in various stages of development for drug-eluting stents.
 
Below is a sampling of the different drugs in development by manufacturers of drug-eluting stents (from report #C245).
 
 
Companies and Drugs for Use in Drug-Eluting Stents
 
Company
Drug
Aachen Resonance GmbH
Paclitaxel
Tretinoin
Abbott Vascular
Dexamethasone
 
Everolimus
 
Dual drug: zotarolimus and dexamethasone
Aeon Bioscience
Undisclosed; polymer-coated
amg International GmbH
Paclitaxel
amg Vascular Products
Paclitaxel
Atrium Medical Corp.
Voclosporin
Avantec Vascular
Pimecrolimus
B. Braun Melsungen
Paclitaxel
Balton
Paclitaxel
Biosensors International
Paclitaxel
Biolimus A9
Biotronik
Pimecrolimus bioabsorbable, CoCr
Blue Medical Devices
Melatonin/paclitaxel combination
Boston Scientific
Paclitaxel
Paclitaxel, second generation
Paclitaxel, third generation, platinum chromium alloy
Paclitaxel, bifurcation
Everolimus
Boston Scientific (developed by Labcoat)
Paclitaxel
CardioMind
Sirolimus; biodegradable to bare metal
CID SRL (formerly Sorin)
Tacrolimus
CorNova
Polymer coated
Devax
Biolimus A9
DISA Vascular
Paclitaxel
Elixir Medical
Myolimus
Novolimus
Estracure
17-beta-estradiol
eucatech AG
Paclitaxel
EuroCor (Opto Circuits)
Paclitaxel
Undisclosed antiproliferative
Global Therapeutics (Cook Medical)
AVI-5126 (CoCr)
ICON Interventional
Deforolimus
InTek
Paclitaxel
ITGI Medical Ltd.
(Undisclosed) Pericardium covered stent
J&J: Conor Medsystems
Pimecrolimus; biodegradable, absorbable
Sirolimus (CoCr)
J&J: Cordis
Sirolimus
Sirolimus (CoCr)
JW Medical Systems
Rapamycin with biodegradable polymer coating
JW Medical Systems (Parent company Shandong Weigao) / Biosensors International
Sirolimus with biodegradable polymer coating
Kaneka
Tacrolimus with biodegradable polymer coating
Lepu Medical (AKA Beijing Lepu Medical Device)
Sirolimus
Medinol/ARIAD Pharmaceuticals
Deforolimus
Medlogics Device Corporation (MDC)
Paclitaxel
“Drug Q”
Medtronic Vascular
Zotarolimus
Micell Technologies
Sirolimus with biodegradable coating
MicroPort Scientific Corporation
Rapamycin
MIV Therapeutics
Sirolimus
mNEMOSCIENCE GmbH
Undisclosed drug, biodegradable, absorbable
NanoInterventions, LLC
(Undisclosed; polymer drug delivery system)
OrbusNeich
Sirolimus; bioabsorbable polymer
Picarus NV
(Undisclosed)
Relisys Medical Devices
Paclitaxel
Sahajanand Medical Technologies
 
Genistein-sirolimus
Paclitaxel
Sirolimus
Heparin-sirolimus
Stentys
Paclitaxel
Terumo
Biolimus A9
Translumina
Rapamycin
Vascular Concepts
Sirolimus
Paclitaxel
VasoTech, Inc.
Paclitaxel, rapamycin (cobalt base)
X-Cell Medical
17-ß-estradiol (XC-121)
Xtent
Biolimus A9
 
Source:  MedMarket Diligence Report #C245, “Worldwide Drug-Eluting, Bare Metal and Other Coronary Stents, 2008-2017.”
 
The market for drug-eluting stents is on a track to be increasingly fragmented and competitive as a result of the aggressive development.  The market is also a moving target as the alternatives multiply and shift with continued demonstration of results (drug-eluting balloons, bioabsorbable stents and the resilience of cardiac surgeons performing CABG). 

Purchase for download:  Report #C245, "Worldwide Coronary Stents 2009, PDF" — $2,850.00
themesmedia/tab_blue_button_add.gif  themesmedia/tab_blue_button_view.gif

Leave a Reply